NCT00372853 - Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

CP-675,206

CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.

DRUG

SU011248

SU011248 administered at a dose of 37.5mg/day every day.

DRUG

CP-675,206

CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.

DRUG

SU011248

SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.

Trial Locations (5)

Research Site, Greenville

Research Site, Memphis

Research Site, Cleveland

Research Site, Scottsdale

Research Site, New Brunswick